Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights
Last patient recruited in the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial with topline results expected in Q3...
Quarter
Alta Equipment Group Announces Third Quarter 2024 Financial
Third Quarter Financial Highlights: Total revenues decreased $17.4 million year over year to $448.8 millionConstruction Equipment and Material Handling revenues...
Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results
Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results Company to host conference call and webcast today at 8:30...
MindMed Reports Second Quarter 2024 Financial Results and Business Updates
--Completed End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA); on track to initiate Phase 3 clinical...
